本文選題：慢性蕁麻疹 + 血虛風(fēng)燥型��； 參考：《湖北中醫(yī)藥大學(xué)》2010年碩士論文

【摘要】： 慢性蕁麻疹是皮膚科的常見(jiàn)多發(fā)疾病,據(jù)臨床報(bào)道統(tǒng)計(jì),約有20%的人一生中都患過(guò)慢性蕁麻疹。慢性蕁麻疹的皮損主要為時(shí)隱時(shí)現(xiàn)的風(fēng)團(tuán),因其經(jīng)常反復(fù)性的發(fā)作、劇癢難忍,進(jìn)而嚴(yán)重影響到患者的工作、學(xué)習(xí)和生活�；颊咭L(zhǎng)期服用抗組胺藥才能控制病情,但停藥后病情很快容易復(fù)發(fā)。所以,防治慢性蕁麻疹是我們醫(yī)護(hù)人員義不容辭的責(zé)任。目前,西醫(yī)治療該病主要是對(duì)癥支持治療,經(jīng)常予以抗組胺藥等內(nèi)服,但副作用較大,且停藥較容易復(fù)發(fā)。我們運(yùn)用養(yǎng)血祛風(fēng)湯聯(lián)合鹽酸西替利嗪內(nèi)服治療慢性蕁麻疹取得了較好的療效。通過(guò)本次臨床研究,目的在于觀察養(yǎng)血祛風(fēng)湯聯(lián)合鹽酸西替利嗪治療血虛風(fēng)燥型慢性蕁麻疹的臨床療效情況以及其復(fù)發(fā)情況,從而為此治療方法在以后的臨床推廣運(yùn)用提供依據(jù)。 所有病例均來(lái)源于2008年8月至2009年5月湖北省中醫(yī)院皮膚科門(mén)診患者,共收集患者60例,均為血虛風(fēng)燥型的慢性蕁麻疹屬患者。將這60例患者隨機(jī)分成治療組和對(duì)照組,各30例。兩組在以下幾個(gè)方面(年齡、性別及病程)經(jīng)統(tǒng)計(jì)學(xué)比較,差異均無(wú)統(tǒng)計(jì)學(xué)意義(P0.05),具有可比性。治療組運(yùn)用養(yǎng)血祛風(fēng)湯煎汁服用,每次150ml,每日2次及口服鹽酸西替利嗪分散片10mg,每日1次。飯后服用。對(duì)照組口服鹽酸西替利嗪分散片10mg,每日1次及口服祛風(fēng)止癢口服液10ml,每日3次。均飯后服用。兩組療程均為四周。服藥期間均停用一切其他藥物。 療效評(píng)價(jià)標(biāo)準(zhǔn)：以癥狀積分下降指數(shù)作為評(píng)判標(biāo)準(zhǔn),癥狀積分下降指數(shù)=[(治療前積分-治療后積分)/治療前積分]×100%。痊愈指標(biāo)：指數(shù)≥90%；顯效指標(biāo)：90%指數(shù)≥60%；有效指標(biāo)：60%指數(shù)≥30%；無(wú)效指標(biāo)：指數(shù)30%。 4.1兩組臨床療效比較,經(jīng)過(guò)統(tǒng)計(jì)學(xué)處理,治療組(養(yǎng)血祛風(fēng)湯聯(lián)合鹽酸西替利嗪)療效優(yōu)于對(duì)照組(鹽酸西替利嗪聯(lián)合祛風(fēng)止癢口服液),具有統(tǒng)計(jì)學(xué)意義(P＜0.05)。 4.2兩組瘙癢程度治療后的評(píng)分比較,經(jīng)過(guò)統(tǒng)計(jì)學(xué)處理,治療組療效優(yōu)于對(duì)照組,具有統(tǒng)計(jì)學(xué)意義(P0.05)。 4.3兩組臨床觀察治療后的總積分比較,經(jīng)過(guò)統(tǒng)計(jì)學(xué)處理,治療組療效優(yōu)于對(duì)照組,具有統(tǒng)計(jì)學(xué)意義(P0.05)。 4.4兩組復(fù)發(fā)率比較,經(jīng)過(guò)統(tǒng)計(jì)學(xué)處理,治療組療效優(yōu)于對(duì)照組,具有統(tǒng)計(jì)學(xué)意義(P0.05)。 通過(guò)對(duì)本次試驗(yàn)的臨床觀察,可以證實(shí)養(yǎng)血祛風(fēng)湯聯(lián)合鹽酸西替利嗪治療血虛風(fēng)燥型慢性蕁麻疹：①其療效優(yōu)于鹽酸西替利嗪組,②同時(shí)其安全性高,毒副反應(yīng)小,經(jīng)濟(jì)適用,為臨床治療慢性蕁麻疹提供了有效的方法。
[Abstract]:Chronic urticaria is a common disease in dermatology. According to clinical report, about 20% of people have had chronic urticaria in their lifetime. The skin lesion of chronic urticaria is mainly a wind mass which is often repeated and itching is hard to bear, which seriously affects the work, study and life of the patients. Patients must take long-term antihistamine to control the condition, but soon after withdrawal of the disease recurrence. Therefore, the prevention and treatment of chronic urticaria is our medical staff's unshirkable responsibility. At present, western medicine treatment is mainly for symptomatic support therapy, often given antihistamine drugs, but the side effects are larger, and withdrawal of drugs is easy to relapse. We used Yangxue Qufeng decoction combined with cetirizine hydrochloride to treat chronic urticaria. The purpose of this clinical study was to observe the clinical efficacy and recurrence of Yangxue Qufeng decoction combined with cetirizine hydrochloride in the treatment of chronic urticaria with blood deficiency and wind dryness. Therefore, the treatment method in the future clinical application to provide the basis. All the cases were from the dermatology department of Hubei traditional Chinese Medicine Hospital from August 2008 to May 2009. A total of 60 cases of chronic urticaria with blood deficiency and wind dryness were collected. The 60 patients were randomly divided into treatment group and control group, 30 cases each. There was no significant difference between the two groups in the following aspects (age, sex and course of disease). The treatment group was treated with Yangxue Qufeng decoction, 150 ml twice a day and 10 mg of cetirizine hydrochloride dispersible tablets once a day. Take it after meals. The control group was treated with 10 mg cetirizine hydrochloride dispersible tablets once a day and 10 ml qufeng Zhiyang oral solution 3 times a day. Take after meals. The course of treatment in both groups was four weeks. All other drugs were discontinued during medication. Evaluation criteria of curative effect: the symptom integral drop index was taken as the criterion, the symptom integral drop index = [(pre-treatment integral-post-treatment integral / pre-treatment integral)] 脳 100. Recovery index: index 鈮，

本文編號(hào)：1778011